We found the study conducted by Huang et al. regarding the involvement of calprotectin (S100A8/9), an inflammatory molecule, in psoriatic arthritis (PsA) quite intriguing. 1 Calprotectin emerges as a valuable indicator of systemic inflammation, particularly when conventional markers like C-reactive protein appear normal. 2,3 It contributes to inflammation not only in the joints but also in the skin, intestines, and cardiovascular system in individuals with PsA. Moreover, the article underscores calprotectin's diagnostic potential in adolescent PsA cases. Furthermore, it delves into the role of DNA methylation in psoriasis, suggesting that genetic susceptibility combined with skin microorganisms might trigger systemic inflammation. This study underscores calprotectin's promise as a biomarker for PsA assessment and its associated complications. Motivated by this, we investigated the commonality of S100A8/9 in the context of treating kidney renal clear cell carcinoma (KIRC) through a comprehensive analysis of publicly available data. In the upcoming sections, we present recent discoveries regarding the clinical relevance of S100A8/9 and its potential role in molding the tumor immune microenvironment in human KIRC. To assess the significance of S100A8/9 expression in KIRC patients, we leveraged public resources such as The Cancer Genome Atlas (TCGA), single-cell RNA sequencing data,